Suchergebnisse - "Guglielmelli, Paola"

PubPharm (388)

1

Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms : a case-control study

enthalten in: Blood cancer journal | 2024

von Ghirardi, A. | Carobbio, A. | Guglielmelli, P. | +5

2

CALR mutation burden in essential thrombocythemia and disease outcome

enthalten in: Blood | 2024

von Guglielmelli, P. | Szuber, N. | Gangat, N. | +15

3

Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion

enthalten in: Blood advances | 2024

von Tretti Parenzan, C. | Molin, A. | Longo, G. | +15

4

ROP-ET : a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options

enthalten in: Annals of hematology | 2024

von Kiladjian, J. | Marin, F. | Al-Ali, H. | +38

5

Inherited polygenic effects on common hematological traits influence clonal selection on JAK2V617F and the development of myeloproliferative neoplasms

enthalten in: Nature genetics | 2024

von Guo, J. | Walter, K. | Quiros, P. | +13

6

Ropeginterferon phase 2 randomized study in low-risk polycythemia vera : 5-year drug survival and efficacy outcomes

enthalten in: Annals of hematology | 2024

von Barbui, T. | Carobbio, A. | De Stefano, V. | +38

7

One thousand patients with essential thrombocythemia : the Florence-CRIMM experience

enthalten in: Blood cancer journal | 2024

von Loscocco, G. | Gesullo, F. | Capecchi, G. | +5

8

A safety evaluation of ruxolitinib for the treatment of polycythemia vera

enthalten in: Expert opinion on drug safety | 2024

von Boldrini, V. | Vannucchi, A. | Guglielmelli, P.

9

Effect of age and treatment on predictive value of measurable residual disease : implications for clinical management of adult patients with acute myeloid leukemia

enthalten in: Haematologica | 2024

von Mannelli, F. | Piccini, M. | Bencini, S. | +18

10

The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis

enthalten in: American journal of hematology | 2024

von Loscocco, G. | Rotunno, G. | Mannelli, F. | +9

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[39]